About OxThera
OxThera has worldwide rights to compounds and methods of use for the treatment of hyperoxaluria. OxThera currently has two products in its portfolio: Oxabact® for the treatment of primary hyperoxaluria and Oxazyme®, an oxalate decarboxylase for the prevention of oxalate malabsorption and recurrent renal stones in secondary hyperoxaluria.
Note: This article has been translated using a computer system without human intervention. LUMITOS offers these automatic translations to present a wider range of company presentation. Since this article has been translated with automatic translation, it is possible that it contains errors in vocabulary, syntax or grammar. The original article in Spanish can be found here.
Facts about OxThera
Facts about OxThera
- Industry : Biotechnology
